CLOAKLINK
Live / Applied — Third extension granted (statement of use) (as of 26 Jan 2026)
What this means for you
Not registered yet, but its 12 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98174937
- Mark type
- Stylized text
- Filed
- 12 Sept 2023
- Published for opposition
- 18 Jun 2024
- Attorney of record
- John Paul Oleksiuk
Goods and services
- Class 005 — Pharmaceuticals: chemical products for medicinal and pharmaceutical use, namely, monoclonal-antibody-drug-conjugate preparations for the treatment of cancer or other indicated human disease; pharmaceutical products for the treatment of cancer, autoimmune diseases, and viral infections; preparations for the medical treatment of cancer consisting of a monoclonal antibody (mAb) or antibody fragment connected to an anti-cancer payload or toxin or immune-stimulant via a chemical linker; chemical reagents for medical use
Owner
- Solve Therapeutics, Inc., Belmont, CA, US
- Solve Therapeutics, Inc., Belmont, CA, US
Prosecution history
- 27 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jan 2026 — SOU EXTENSION 3 GRANTED
- 26 Jan 2026 — SOU EXTENSION 3 FILED
- 26 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 01 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Jul 2025 — SOU EXTENSION 2 GRANTED
- 31 Jul 2025 — SOU EXTENSION 2 FILED
- 31 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Feb 2025 — SOU EXTENSION 1 GRANTED
- 11 Feb 2025 — SOU EXTENSION 1 FILED
- 11 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Jun 2024 — PUBLISHED FOR OPPOSITION